文献速递心境障碍

重性抑郁障碍的转录组谱:免疫代谢与细胞周期相关通路在不同炎症水平抑郁中的作用

Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation.
PubMed 文献 · Mol Psychiatry · 2024-09-13

该观察性病例对照研究对BIODEP研究中105例重性抑郁障碍患者和34名对照进行全血RNA测序及通路分析,按血清超敏C反应蛋白水平将患者分为未发炎(CRP<1 mg/L,39例)、CRP升高(1-3 mg/L,31例)和低度炎症(>3 mg/L,35例)三组,发现CRP>1 mg/L者免疫代谢通路激活,CRP<1组与对照比较以细胞周期相关通路为主,应答者存在特定免疫调节和神经保护通路。

要点

  • CRP>1 mg/L的抑郁患者免疫代谢通路激活,但CRP 1-3组免疫激活强于CRP>3组。
  • CRP<1 mg/L抑郁组与对照比较以细胞周期相关通路为主,可能对该组免疫代谢异常有保护作用。
  • 应答者存在特定免疫调节和神经保护通路,尤其与非应答者比较,可能和治疗应答相关。

核心结论

  • 本研究显示重性抑郁障碍及其不同(基于CRP和基于治疗的)表型与免疫代谢和细胞周期相关转录组通路有关,并揭示可能预防或促进个体走向免疫代谢性抑郁和/或治疗无应答抑郁的潜在分子机制。

研究设计与样本

  • 对BIODEP(重性抑郁障碍生物标志物)观察性病例对照研究中139名个体(105例重性抑郁障碍患者和34名对照)进行全转录组和通路分析。

主要发现

  • CRP>1 mg/L的个体免疫代谢通路激活,但CRP 1-3 mg/L组(31例)免疫激活强于CRP>3 mg/L组(35例)。
  • CRP<1 mg/L组(39例)与对照比较的主要通路为细胞周期相关,可能对该非发炎抑郁组的免疫代谢异常有保护作用。
  • 按抗抑郁药暴露和应答分组的亚组分析中,应答者(37例)尤其与非应答者(47例)比较存在特定免疫调节和神经保护通路。
  • 进一步亚组分析发现应答者的特定转录谱独立于CRP水平,且CRP<1 mg/L重性抑郁障碍中细胞周期相关通路抑制仅见于当前抑郁者,不见于应答者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transcriptomic profiles are important indicators for molecular mechanisms and pathways involved in major depressive disorder (MDD) and its different phenotypes, such as immunometabolic depression. We performed whole-transcriptome and pathway analyses on 139 individuals from the observational, case-control, BIOmarkers in DEPression (BIODEP) study, 105 with MDD and 34 controls. We divided MDD participants based on levels of inflammation, as measured by serum high-sensitivity C-reactive protein (CRP), in n = 39 'not inflamed' (CRP < 1 mg/L), n = 31 with 'elevated CRP' (1-3 mg/L), and n = 35 with 'low-grade inflammation' (>3 mg/L). We performed whole-blood RNA sequencing using Illumina NextSeq 550 and statistical analyses with the Deseq2 package for R statistics (RUV-corrected) and subsequent pathway analyses with Ingenuity Pathway Analysis. Immunometabolic pathways were activated in individuals with CRP > 1 mg/L, although surprisingly the CRP 1-3 group showed stronger immune activation than the CRP > 3 group. The main pathways identified in the comparison between CRP < 1 group and controls were cell-cycle-related, which may be protective against immunometabolic abnormalities in this 'non-inflamed' depressed group. We further divided MDD participants based on exposure and response to antidepressants (n = 47 non-responders, n = 37 responders, and n = 22 unmedicated), and identified specific immunomodulatory and neuroprotective pathways in responders (especially vs. non-responders), which could be relevant to treatment response. In further subgroup analyses, we found that the specific transcriptional profile of responders is independent of CRP levels, and that the inhibition of cell-cycle-related pathways in MDD with CRP < 1 mg/L is present only in those who are currently depressed, and not in the responders. The present study demonstrates immunometabolic and cell-cycle-related transcriptomic pathways associated with MDD and different (CRP-based and treatment-based) MDD phenotypes, while shedding light on potential molecular mechanisms that could prevent or facilitate an individual's trajectory toward immunometabolic depression and/or treatment-non-responsive depression. The recognition and integration of these mechanisms will facilitate a precision-medicine approach in MDD.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Sforzini L, Marizzoni M, Bottanelli C, et al. Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation. Mol Psychiatry. 2024. PMID: 39271754. doi:10.1038/s41380-024-02736-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。